Bleeding Rates With Concomitant Ibrutinib and Oral Anticoagulant Therapy
abstract
This abstract is available on the publisher's site.
Access this abstract nowIbrutinib, a Bruton's tyrosine kinase inhibitor, has transformed treatment strategies for B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Clinical trials found that ibrutinib produces high progression-free survival and overall response rates in CLL, MCL, and MZL, and has a favorable safety profile compared to chemotherapy. However, bleeding occurs in up to 50% of patients—sometimes leading to serious consequences such as hospitalization or death.
Additional Info
Bleeding with concomitant ibrutinib and oral anticoagulant therapy: A population-based cohort study
Am. J. Hematol 2022 Dec 02;[EPub Ahead of Print], N Dhopeshwarkar, W Yang, S Hennessy, JM Rhodes, A Cuker, CE LeonardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.